AN2 Therapeutics, Inc.
ANTX
$1.15
$0.043.60%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -6.46M | -10.65M | -7.52M | -12.75M | -14.44M |
Total Depreciation and Amortization | -- | -- | -- | -- | -- |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 1.70M | 1.60M | 1.21M | 1.17M | 1.38M |
Change in Net Operating Assets | -2.84M | -1.58M | 1.04M | -431.00K | -1.33M |
Cash from Operations | -7.60M | -10.62M | -5.27M | -12.01M | -14.38M |
Capital Expenditure | -- | -- | -- | -- | -- |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 5.83M | 9.19M | -6.88M | 18.72M | 16.46M |
Cash from Investing | 5.83M | 9.19M | -6.88M | 18.72M | 16.46M |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 0.00 | 65.00K | 0.00 | 23.00K | 0.00 |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | 0.00 | 65.00K | 0.00 | 23.00K | 0.00 |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -1.77M | -1.37M | -12.15M | 6.74M | 2.08M |